عرض سجِل بسيط للمادة

dc.contributor.authorWorld Health Organizationen_US
dc.coverage.spatialGenevaen_US
dc.date.accessioned2018-12-20T09:27:00Z
dc.date.available2018-12-20T09:00:00Z
dc.date.issued2018
dc.identifier.govdocWHO/RHR/18.28
dc.identifier.urihttps://iris.who.int/handle/10665/277277
dc.description19 p.en_US
dc.language.isoenen_US
dc.publisherWorld Health Organizationen_US
dc.rightsCC BY-NC-SA 3.0 IGOen_US
dc.rights.urihttps://creativecommons.org/licenses/by-nc-sa/3.0/igoen_US
dc.subject.meshMaternal Healthen_US
dc.subject.meshPostpartum Hemorrhageen_US
dc.subject.meshGuidelineen_US
dc.subject.meshObstetric Labor Complicationsen_US
dc.subject.meshChild Healthen_US
dc.titleWHO recommendations Uterotonics for the prevention of postpartum haemorrhage: Web annex 1: Oxytocin versus placebo or no treatmenten_US
dc.typeTechnical documentsen_US
dc.rights.holderWorld Health Organizationen_US


الملفات في هذه المادة

Thumbnail

هذه المادة تظهر في المجموعات التالية

عرض سجِل بسيط للمادة